Your browser doesn't support javascript.
loading
Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report.
Bousquet, Jean; Shamji, Mohamed H; Anto, Josep M; Schünemann, Holger J; Canonica, G Walter; Jutel, Marek; Del Giacco, Stefano; Zuberbier, Torsten; Pfaar, Oliver; Fonseca, Joao A; Sousa-Pinto, Bernardo; Klimek, Ludger; Czarlewski, Wienczyslawa; Bedbrook, Anna; Amaral, Rita; Ansotegui, Ignacio J; Bosnic-Anticevich, Sinthia; Braido, Fulvio; Chaves Loureiro, Claudia; Gemicioglu, Bilun; Haahtela, Tari; Kulus, Marek; Kuna, Piotr; Kupczyk, Maciej; Matricardi, Paolo M; Regateiro, Frederico S; Samolinski, Boleslaw; Sofiev, Mikhail; Toppila-Salmi, Sanna; Valiulis, Arunas; Ventura, Maria Teresa; Barbara, Cristina; Bergmann, Karl C; Bewick, Michael; Blain, Hubert; Bonini, Matteo; Boulet, Louis-Philippe; Bourret, Rodolphe; Brusselle, Guy; Brussino, Luisa; Buhl, Roland; Cardona, Victoria; Casale, Thomas; Cecchi, Lorenzo; Charpin, Denis; Cherrez-Ojeda, Ivan; Chu, Derek K; Cingi, Cemal; Costa, Elisio M; Cruz, Alvaro A.
Afiliación
  • Bousquet J; Institute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Shamji MH; University Hospital Montpellier, Montpellier, France.
  • Anto JM; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
  • Schünemann HJ; National Heart and Lung Institute (NHLI), Imperial College London, London, UK.
  • Canonica GW; NIHR Imperial Biomedical Research Centre, London, UK.
  • Jutel M; ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.
  • Del Giacco S; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Zuberbier T; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
  • Pfaar O; Department of Health Research Methods, Evidence, and Impact, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Fonseca JA; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Sousa-Pinto B; Personalized Medicine, Asthma & Allergy, IRCCS Humanitas Research Center, Milan, Italy.
  • Klimek L; Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.
  • Czarlewski W; ALL-MED Medical Research Institute, Wroclaw, Poland.
  • Bedbrook A; Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula," University of Cagliari, Cagliari, Italy.
  • Amaral R; Institute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ansotegui IJ; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
  • Bosnic-Anticevich S; Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
  • Braido F; MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Chaves Loureiro C; CINTESIS@RISE- Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Gemicioglu B; MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Haahtela T; CINTESIS@RISE- Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Kulus M; Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany.
  • Kuna P; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Kupczyk M; Medical Consulting Czarlewski, Levallois, France.
  • Matricardi PM; MASK-air, Montpellier, France.
  • Regateiro FS; MASK-air, Montpellier, France.
  • Samolinski B; ARIA, Montpellier, France.
  • Sofiev M; MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Toppila-Salmi S; CINTESIS@RISE- Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Valiulis A; Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.
  • Ventura MT; Quality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Sydney, New South Wales, Australia.
  • Barbara C; Sydney Local Health District, Sydney, New South Wales, Australia.
  • Bergmann KC; Sydney Pharmacy School, The University of Sydney, Sydney, New South Wales, Australia.
  • Bewick M; Respiratory Clinic, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Blain H; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Bonini M; Pneumology Unit, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
  • Boulet LP; Department of Pulmonary Diseases, Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
  • Bourret R; Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Brusselle G; Department of Pediatric Respiratory Diseases and Allergology, Medical University of Warsaw, Warsaw, Poland.
  • Brussino L; Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
  • Buhl R; Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
  • Cardona V; Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Casale T; Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
  • Cecchi L; Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (ICBR), University of Coimbra, Coimbra, Portugal.
  • Charpin D; Faculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal.
  • Cherrez-Ojeda I; Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland.
  • Chu DK; Finnish Meteorological Institute (FMI), Helsinki, Finland.
  • Cingi C; Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Costa EM; Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania.
  • Cruz AA; Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.
Allergy ; 78(7): 1758-1776, 2023 07.
Article en En | MEDLINE | ID: mdl-37042071
ABSTRACT
Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastornos Respiratorios / Asma / Rinitis / Rinitis Alérgica Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Allergy Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastornos Respiratorios / Asma / Rinitis / Rinitis Alérgica Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Allergy Año: 2023 Tipo del documento: Article País de afiliación: Alemania